On June 14, 2024, XNW27011, a new-generation Antibody-Coupled Drug (ADC) developed by Evopoint, has been granted Fast Track Designation (FTTD) statu...
Evopoint independently developed a new small molecule selective URAT1 inhibitor, XNW3009.
In the upcoming Year of the Loong, prosperity is anticipated, as the Dragon spreads its wings. Evopoint Biosciences Co., Ltd. (hereinafter referred ...